Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology

Standard of Care Treatment Options

At a Glance

Treatment for Castleman disease depends entirely on the subtype. Unicentric Castleman Disease (UCD) is typically cured with surgical removal. Multicentric subtypes require systemic medications, such as siltuximab to block IL-6 inflammation, or rituximab to target the HHV-8 virus.

Treating Castleman disease (CD) requires a tailored approach based on your specific subtype. In 2020, the Castleman Disease Collaborative Network (CDCN) published updated international guidelines to ensure that patients receive the most effective, evidence-based care available [1][2].

Unicentric Castleman Disease (UCD): The Goal is a Cure

For UCD, the standard of care is straightforward: complete surgical resection [1][3].

  • The Preferred Path: If the affected lymph node can be safely removed, surgery is often curative, and most patients do not require further treatment [1][4].
  • If Surgery Isn’t Possible: If a node is unresectable (cannot be safely removed because it is too close to vital organs or blood vessels), other options include:
    • Embolization: Shrinking the node by cutting off its blood supply [1].
    • Radiotherapy: Using targeted radiation to shrink the node [1][5].
    • Anti-IL-6 Therapy: Using medications like siltuximab to manage symptoms and shrink the mass before attempting surgery again [1][6].

Idiopathic Multicentric CD (iMCD): Managing the Systemic Fire

Because iMCD involves the whole body, it requires systemic (medicine-based) treatment rather than surgery.

  • First-Line Therapy: The “gold standard” for iMCD is siltuximab, an anti-IL-6 monoclonal antibody, which is delivered as an IV infusion usually every 3 weeks [7][8]. It works by soaking up the excess IL-6 protein in your blood, essentially “putting out the fire” of inflammation [9]. Symptom relief can sometimes be felt within days or weeks, though shrinking the lymph nodes takes longer [9].
  • Alternative: If siltuximab is not available, tocilizumab (which blocks the IL-6 receptor via IV infusion) may be used [10][11].
  • For Severe Cases (TAFRO): The TAFRO variant is often considered a medical emergency and requires aggressive, immediate intervention [12][13]. Doctors typically use high-dose corticosteroids combined with siltuximab [10][14]. While necessary, high-dose steroids can cause severe temporary side effects like insomnia, mood changes, and fluid retention. If the disease is “refractory” (doesn’t respond), doctors may add JAK inhibitors (like ruxolitinib) or cyclosporine A to gain control [15][14].

HHV-8 Associated MCD: Targeting the Virus and the B-Cells

When the disease is driven by the HHV-8 virus, the treatment strategy shifts to focus on the cells where the virus lives.

  • Rituximab: This is the primary treatment for HHV-8 MCD, given as an IV infusion [16][17]. It targets and removes B-cells, which effectively reduces the “viral load” in the body [16]. Important: Rituximab carries significant risks, including severe immunosuppression and the potential for Hepatitis B reactivation, so you must be screened for Hepatitis B before starting treatment [16].
  • Combination Therapy: For patients with severe symptoms or organ dysfunction, doctors often combine rituximab with chemotherapy, such as liposomal doxorubicin [16][18]. This combination can lead to a rapid resolution of the life-threatening inflammation caused by the virus [16].

POEMS-Associated MCD: Treating the Source

For patients with POEMS-associated MCD, treating the Castleman disease alone is not enough. Treatment focuses on the underlying plasma cell disorder, often involving radiation, chemotherapy, or stem cell transplant to target the abnormal cells producing VEGF [19].

Treatment Summary Table

Subtype Primary Treatment Goal of Therapy
UCD Surgery (Resection) Complete Cure [1]
iMCD-NOS Siltuximab (IV infusion) Long-term Disease Control [7]
iMCD-TAFRO Siltuximab + High-dose Steroids Rapid Stabilization & Control [10]
HHV-8 MCD Rituximab ± Chemotherapy Clear Virus & Control Inflammation [16]
POEMS MCD Directed at Plasma Cell Disorder Eliminate Underlying Source [19]

Note: While many UCD patients are cured, doctors recommend long-term follow-up because late relapses, though rare, can occur years later [20][21].

Common questions in this guide

Is surgery enough to cure Unicentric Castleman Disease (UCD)?
For most patients with Unicentric Castleman Disease, complete surgical removal of the affected lymph node is curative. However, long-term follow-up is still recommended to monitor for rare relapses that can occur years later.
What happens if my UCD lymph node cannot be safely removed with surgery?
If the affected lymph node is too close to vital organs or blood vessels, doctors may use other treatments. These include targeted radiation, embolization to cut off the node's blood supply, or medications like siltuximab to shrink the mass.
What is the standard treatment for Idiopathic Multicentric Castleman Disease (iMCD)?
The primary treatment for iMCD is siltuximab, an intravenous medication that blocks a protein called IL-6. This medication helps reduce systemic inflammation and manage symptoms, typically requiring infusions every three weeks.
Are there specific treatments for the TAFRO variant of Castleman disease?
The TAFRO variant often requires immediate, aggressive treatment. Doctors typically use high-dose corticosteroids combined with siltuximab, and may add medications like JAK inhibitors if the disease does not initially respond.
How is HHV-8 associated Multicentric Castleman Disease treated?
Treatment for the HHV-8 variant focuses on reducing the viral load by targeting B-cells, primarily using the medication rituximab. Before starting this treatment, patients must be screened for Hepatitis B to prevent viral reactivation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my surgical plan for Unicentric Castleman Disease (UCD) aim for complete resection, and what is our plan if the node is considered unresectable?
  2. 2.Since I have iMCD, am I a candidate for siltuximab as my first-line therapy, and how often will I receive infusions?
  3. 3.For my HHV-8 positive MCD, should we be starting rituximab, and have I been screened for Hepatitis B to prevent reactivation?
  4. 4.If my iMCD-TAFRO symptoms don't improve with steroids and IL-6 inhibitors, at what point do we consider 'salvage' therapies like JAK inhibitors?
  5. 5.How frequently will we monitor my lab results (like CRP and hemoglobin) to determine if the treatment is working?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

    van Rhee F, Oksenhendler E, Srkalovic G, et al.

    Blood advances 2020; (4(23)):6039-6050 doi:10.1182/bloodadvances.2020003334.

    PMID: 33284946
  2. 2

    Multicentric Castlemans disease. Symptoms, diagnostics and therapy.

    Adam Z, Řehák Z, Adamová Z, et al.

    Vnitrni lekarstvi 2022; (68(1)):41-53.

    PMID: 35459346
  3. 3

    Pelvic unicentric Castleman's disease mimicking accessory spleen: A rare presentation of Castleman's disease, a case report and literature report.

    Emiru ZA, Getahun AM, Kassie YG, et al.

    International journal of surgery case reports 2025; (129()):111177 doi:10.1016/j.ijscr.2025.111177.

    PMID: 40106952
  4. 4

    Unicentric Castleman Disease.

    Wong RSM

    Hematology/oncology clinics of North America 2018; (32(1)):65-73 doi:10.1016/j.hoc.2017.09.006.

    PMID: 29157620
  5. 5

    [Unicentric Castleman disease: a blind lymph node.]

    Rizzi S, Polenzani I, Troisi A, et al.

    Recenti progressi in medicina 2021; (112(10)):653-658 doi:10.1701/3679.36656.

    PMID: 34647535
  6. 6

    Unicentric Castlemans disease. Symptoms, diagnostics and therapy.

    Adam Z, Řehák Z, Adamová Z, et al.

    Vnitrni lekarstvi 2021; (67(8)):465-473.

    PMID: 35459366
  7. 7

    CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease.

    Pierson SK, Katz L, Williams R, et al.

    Nature communications 2022; (13(1)):7236 doi:10.1038/s41467-022-34873-7.

    PMID: 36433996
  8. 8

    Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

    Pelliccia S, Di Rocco A, Palumbo G, et al.

    Frontiers in oncology 2026; (16()):1762473 doi:10.3389/fonc.2026.1762473.

    PMID: 41777649
  9. 9

    The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.

    Min GJ, Jeon YW, Park SS, et al.

    The Korean journal of internal medicine 2021; (36(2)):424-432 doi:10.3904/kjim.2019.330.

    PMID: 32088937
  10. 10

    [Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report].

    Yi P, Zhang XX, Tang T, et al.

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2025; (27(5)):613-617 doi:10.7499/j.issn.1008-8830.2412050.

    PMID: 40462437
  11. 11

    Idiopathic multicentric Castleman disease-TAFRO after COVID-19: A case report.

    Shiina T, Yamamoto EK, Yamada H, et al.

    Modern rheumatology case reports 2025; (9(1)):174-178 doi:10.1093/mrcr/rxae045.

    PMID: 39177383
  12. 12

    Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.

    Bustamante MS, Pierson SK, Ren Y, et al.

    Haematologica 2024; (109(7)):2196-2206 doi:10.3324/haematol.2023.283603.

    PMID: 38205523
  13. 13

    TAFRO Syndrome.

    Igawa T, Sato Y

    Hematology/oncology clinics of North America 2018; (32(1)):107-118 doi:10.1016/j.hoc.2017.09.009.

    PMID: 29157612
  14. 14

    Successful Treatment of TAFRO (Thrombocytopenia, Anasarca, Fever, Renal Insufficiency, and Organomegaly) Syndrome With Triple Combination Therapy of Corticosteroid, Tocilizumab, and Cyclosporine: A Case Report.

    Morino J, Hirai K, Yoshida K, et al.

    Cureus 2025; (17(3)):e80274 doi:10.7759/cureus.80274.

    PMID: 40201884
  15. 15

    Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: A case report.

    Kakutani T, Nunokawa T, Chinen N, Tamai Y

    Medicine 2022; (101(48)):e32200 doi:10.1097/MD.0000000000032200.

    PMID: 36482523
  16. 16

    Severe polyneuropathy in HIV-negative human herpesvirus 8-associated multicentric Castleman disease successfully treated with rituximab and liposomal doxorubicin.

    Takahashi S, Yoshihara K, Fujii T, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2026; (32(4)):102934 doi:10.1016/j.jiac.2026.102934.

    PMID: 41720336
  17. 17

    Clinical response to liposomal doxorubicin and rituximab in HHV-8-associated multicentric Castleman's disease in an HIV-positive patient.

    Osa M, Maeda T, Misawa K, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2016; (22(12)):804-807 doi:10.1016/j.jiac.2016.06.004.

    PMID: 27373909
  18. 18

    A HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and valganciclovir combination.

    Kantarci FE, Eren R, Gündoğan C, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2016; (22(7)):483-5.

    PMID: 26948831
  19. 19

    POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management.

    Dispenzieri A

    American journal of hematology 2021; (96(7)):872-888 doi:10.1002/ajh.26240.

    PMID: 34000085
  20. 20

    Unicentric Castleman's disease located between the aorta and inferior vena cava: A case report.

    Murata M, Nagano O, Hasegawa G, et al.

    SAGE open medical case reports 2019; (7()):2050313X19839532 doi:10.1177/2050313X19839532.

    PMID: 30984398
  21. 21

    Recurrence in unicentric castleman's disease postoperatively: a case report and literature review.

    Ren N, Ding L, Jia E, Xue J

    BMC surgery 2018; (18(1)):1 doi:10.1186/s12893-017-0334-7.

    PMID: 29301533

This page provides educational information about standard treatments for Castleman disease subtypes. Always consult your hematologist or oncologist to determine the safest and most effective treatment plan for your specific condition.

Get notified when new evidence is published on Castleman disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.